Swedish biotechnology company Alligator Bioscience AB (STO:ATORX) announced on Tuesday that the US Patent and Trademark Office has granted US Patent No. 12,448,465 covering ATOR-4066, its bispecific antibody targeting CD40 and CEACAM5.

The new patent, formally issued on 21 October 2025, provides broad protection for the antibody and its unique binding regions and is expected to remain in force until 2043, excluding extensions.

ATOR-4066 is designed to activate CD40 on antigen-presenting cells while targeting CEACAM5 on tumour cells, bridging immune activation and tumour recognition. Preclinical studies have shown potent anti-tumour activity, and the candidate is advancing toward clinical development within Alligator's next-generation immuno-oncology pipeline. The programme leverages the company's experience with mitazalimab, its lead CD40 agonist in pivotal development for pancreatic cancer.

Alligator also has a continuation patent application pending in the United States, aiming to further expand protection around ATOR-4066.